Premium
enGene Therapeutics Inc (ENGN)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-01-30 | Dr. Anthony T. CheungCo-Founder & Chief Scientific Officer | 195,00k | 0,00 | Derivative Acquisition Under Employee Benefit Plan | 7,03 | 977,57k | 24,92% |
| 2026-01-30 | Ms. Joan ConnollyCTO | 195,00k | 0,00 | Derivative Acquisition Under Employee Benefit Plan | 7,03 | 405,00k | 92,86% |
| 2026-01-30 | Ms. Jill BuckChief Development Officer | 195,00k | 0,00 | Derivative Acquisition Under Employee Benefit Plan | 7,03 | 414,00k | 89,04% |
| 2026-01-30 | Mr. Ronald H. W. CooperPresident, CEO & Director | 801,00k | 0,00 | Derivative Acquisition Under Employee Benefit Plan | 7,03 | 2,90M | 38,14% |
| 2026-01-30 | Mr. Matthew BoydChief Regulatory Officer | 195,00k | 0,00 | Derivative Acquisition Under Employee Benefit Plan | 7,03 | 414,00k | 89,04% |
| 2025-09-30 | Dr. Hussein SweitiInitié | 600,00k | 0,00 | Derivative Acquisition Under Employee Benefit Plan | - | 600,00k | - |
| 2025-07-08 | Mr. Philip Astley-SparkeIndependent Non-Executive Director | 45,00k | 0,00 | Derivative Acquisition Under Employee Benefit Plan | - | 45,00k | - |
| 2025-07-08 | Ms. Jill BuckChief Development Officer | 100,00k | 0,00 | Derivative Acquisition Under Employee Benefit Plan | - | 219,00k | 84,03% |
| 2025-07-08 | Mr. Matthew BoydChief Regulatory Officer | 100,00k | 0,00 | Derivative Acquisition Under Employee Benefit Plan | - | 219,00k | 84,03% |
| 2025-07-08 | Mr. Michael Thomas HeffernanIndependent Non-Executive Director | 45,00k | 0,00 | Derivative Acquisition Under Employee Benefit Plan | - | 45,00k | - |
| 2025-07-08 | Dr. William J. GrossmanInterim Chief Medical Officer & Director | 45,00k | 0,00 | Derivative Acquisition Under Employee Benefit Plan | - | 45,00k | - |
| 2025-07-08 | Ms. Jill BuckChief Development Officer | 119,00k | 0,00 | Derivative Acquisition Under Employee Benefit Plan | - | 119,00k | - |
| 2025-07-08 | Mr. Matthew BoydChief Regulatory Officer | 119,00k | 0,00 | Derivative Acquisition Under Employee Benefit Plan | - | 119,00k | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
